Rybrevant (amivantamab-vmjw) was approved for adults with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, the U.S. Food and Drug […]
The B16172 variant is now dominant in the UK, and there have been fears that its sudden rise could derail Britain’s exit from lockdown. Scientists—including me—have […]